Ixabepilone: a new active chemotherapy in the treatment of breast cancer. - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Womens Health (Lond Engl) Année : 2009

Ixabepilone: a new active chemotherapy in the treatment of breast cancer.

Résumé

Ixabepilone (BMS247550) is a semisynthetic derivative of the natural product that optimizes the properties observed with epothilone B. This compound has some similarities with taxanes in targeting and stabilizing microtubules, but it also has major differences. Interestingly, ixabepilone was evaluated in patients with well-characterized resistance to taxanes and was able to overcome the overexpression of multidrug resistance and was unaffected by mutations in the beta-tubulin genes. The interest in ixabepilone was clinically confirmed in Phase II and III clinical studies, which have demonstrated a strong activity in patients with metastatic breast cancer resistant to taxanes and in patients suffering from other types of chemoresistant tumors.

Domaines

Immunologie

Dates et versions

inserm-00484429 , version 1 (18-05-2010)

Identifiants

Citer

Cristian Villanueva, Antoine Thiery Vuillemin, Martin Demarchi, Fernando Bazan, Loïc Chaigneau, et al.. Ixabepilone: a new active chemotherapy in the treatment of breast cancer.. Womens Health (Lond Engl), 2009, 5 (2), pp.115-21. ⟨10.2217/17455057.5.2.115⟩. ⟨inserm-00484429⟩

Collections

INSERM UNIV-FCOMTE
59 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More